Latest news
Showing 24/1505 results
Astex and the NCIC Clinical Trials Group Announce Start of Phase II Clinical Study of AT9283 in Multiple Myeloma
None
Thu 4 Nov 2010
TP+ October Newsletter
None
Mon 1 Nov 2010
Life Sciences
Research from Cambridge Consultants Identifies Solutions to Address Global Drug Counterfeiting Epidemic
None
Thu 28 Oct 2010
Invista unveil latest refurbishment project at Cambridge Science Park
Thu 28 Oct 2010
Milestone transition in Astex Alzheimer’s Disease collaboration with AstraZeneca
AstraZeneca has selected a candidate drug from its collaborative drug discovery programme aimed at identifying novel, small molecule inhibitors of beta-secretase - a key enzyme implicated in the progression of Alzheimer’s disease.
Thu 28 Oct 2010
The Cambridge Fun Run - 19 Nov 2010
None
Thu 28 Oct 2010
TP+ Cycle Maintenance Courses
None
Tue 26 Oct 2010
Take-up continues at 101 Cambridge
None
Mon 25 Oct 2010
Cambridge businesses join forces to help homeless youngsters
None
Wed 6 Oct 2010
Technology
Wireless Experts Say The Signal Is Clear For Whitespace
None
Wed 6 Oct 2010
Festival of Ideas 2010
None
Wed 29 Sep 2010
TP+ Bicycle User Group Meeting
None
Wed 29 Sep 2010
Technology
picoChip and Cambridge Consultants collaborate on LTE Femtocell platform enhancement
None
Thu 23 Sep 2010
Global Poverty and ICTs
None
Mon 20 Sep 2010
The British Science Association in Cambridge
The British Science Association are looking for enthusiastic volunteers to join their new Cambridgeshire branch.
Mon 6 Sep 2010
Technology
Breathe™ easy: Cambridge Consultants technology adds intelligence and automation to aspiration procedures
None
Fri 27 Aug 2010
Putting the patient first: students work with elderly to define the next stage of the connected health revolution
None
Fri 20 Aug 2010
Astex and Multiple Myeloma Research Consortium (MMRC) Announce Start of Phase II Clinical Study of AT7519 in Multiple Myeloma
Cambridge, UK, and Norwalk, Connecticut, USA, 12 August 2010. Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium (MMRC) announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase (CDK) inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).
Mon 16 Aug 2010
FREE - Commuter Stand Service
None
Fri 30 Jul 2010
ASIAN PROGRESS FOR OWLSTONE
A new order from a Japanese technology company for FAIMS development platforms has been received by Owlstone’s Cambridge UK laboratories.
Mon 26 Jul 2010
Life Sciences
CAMBRIDGE COMPANY WINS ‘OSCAR OF INNOVATION’
Owlstone Nanotech, Inc., in partnership with Pacific Northwest National Laboratory, has been selected as one of the 2010 R&D100 Award winners.
Mon 26 Jul 2010
Warning: ITC Group
None
Thu 15 Jul 2010
Congrats to Cambridge Cycle Challenge Winners
None
Thu 15 Jul 2010
Cambridge Consultants making a splash in the innovative marine industry
None
Wed 14 Jul 2010